It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstrak
Down syndrome is the most frequent chromosomal abnormality among live-born infants. All Down syndrome patients have mental retardation and are prone to develop early onset Alzheimer’s disease. However, it has not yet been elucidated whether there is a correlation between the phenotype of Down syndrome and the extra chromosome 21. In this study, we continuously cultivated induced pluripotent stem cells (iPSCs) with chromosome 21 trisomy for more than 70 weeks, and serendipitously obtained revertant cells with normal chromosome 21 diploids from the trisomic cells during long-term cultivation. Repeated experiments revealed that this trisomy rescue was not due to mosaicism of chromosome 21 diploid cells and occurred at an extremely high frequency. We herewith report the spontaneous correction from chromosome 21 trisomy to disomy without genetic manipulation, chemical treatment or exposure to irradiation. The revertant diploid cells will possibly serve a reference for drug screening and a raw material of regenerative medicinal products for cell-based therapy.
Continuously cultivated iPSCs with chromosome 21 trisomy spontaneously reverted to normal diploids. This trisomy rescue occurred without genetic manipulation, chemical treatment, or exposure to irradiation. The revertant cells can serve as a reference for drug screening and as raw materials for regenerative medicine and cell-based therapy.
Anda meminta layanan mesin penerjemahan "on-the-fly" untuk materi yang Anda pilih dari basis data kami. Fungsionalitas ini diberikan untuk kemudahan semata dan tidak dimaksudkan untuk mengganti terjemahan manusia. Tampilkan penafian lengkap
Baik ProQuest maupun para pemberi lisensinya tidak memberikan pernyataan atau jaminan apa pun terkait terjemahan tersebut. Terjemahan ini dihasilkan secara otomatis "SEBAGAIMANA ADANYA" dan "SEBAGAIMANA TERSEDIA" dan tidak disimpan dalam sistem kami. PROQUEST DAN PARA PEMBERI LISENSINYA SECARA KHUSUS MENAFIKAN SETIAP DAN SEMUA JAMINAN BAIK TERSURAT MAUPUN TERSIRAT, TERMASUK TANPA PEMBATASAN, SEGALA JAMINAN ATAS KETERSEDIAAN, AKURASI, AKTUALITAS, KELENGKAPAN, KEPATUHAN, KETERJUALAN, ATAU KECOCOKAN UNTUK TUJUAN TERTENTU. Penggunaan Anda atas terjemahan ini tunduk pada semua pembatasan penggunaan yang termuat dalam Perjanjian Lisensi Produk Elektronik dan dengan menggunakan fungsionalitas terjemahan ini Anda setuju untuk melepas setiap dan semua klaim terhadap ProQuest atau para pemberi lisensinya terkait penggunaan Anda atas fungsionalitas penerjemahan ini dan setiap keluaran yang diperoleh darinya. Sembunyikan penafian lengkap
Detail

1 National Center for Child Health and Development, Department of Reproductive Biology, Tokyo, Japan (GRID:grid.63906.3a) (ISNI:0000 0004 0377 2305); The Jikei University School of Medicine, Department of Obstetrics and Gynecology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
2 National Center for Child Health and Development, Department of Reproductive Biology, Tokyo, Japan (GRID:grid.63906.3a) (ISNI:0000 0004 0377 2305)
3 National Cancer Center Research Institute, Division of Carcinogenesis and Cancer Prevention, Department of Cell Culture Technology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385)
4 The Jikei University School of Medicine, Department of Obstetrics and Gynecology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
5 National Center for Child Health and Development, Department of Maternal-Fetal, Neonatal and Reproductive Medicine, Tokyo, Japan (GRID:grid.63906.3a) (ISNI:0000 0004 0377 2305)